Jan. 2, 2019—Vanderbilt's Center for Technology Transfer and Commercialization, the Vanderbilt Institute of Chemical Biology and Deerfield will bring together experts in discovery and development of antibody therapeutics Jan. 23 to discuss and review state-of-the-art developments in the field.
Dec. 19, 2018—The event aims to expose faculty and staff to therapeutic antibody discovery in an academic setting and foster interest in submission of innovative ideas for antibody targets through an upcoming RFP for Ancora, the collaboration between Vanderbilt and Deerfield.
Dec. 17, 2018—Ten years after Professor of Biomedical Engineering Anita Mahadevan-Jansen discovered that parathyroid tissues glow under near-infrared light, the FDA has approved a device based on the technology for surgical use.
Nov. 26, 2018—Ancora Innovation, LLC, the new collaboration between Vanderbilt and Deerfield Management established earlier this year, has completed its inaugural proposal review process and announced two projects selected for funding.
Oct. 7, 2018—Vanderbilt's Center for Technology Transfer and Commercialization will host a session on Oct. 16 with the Harrington Discovery Institute to explore funding opportunities for physicians and scientists who are developing new therapies.
May. 10, 2018—The Office of the Vice Provost for Research and the Center for Technology Transfer and Commercialization have posted informational slides for faculty preparing pre-proposal submissions in response to the inaugural Ancora request for proposals.
Apr. 20, 2018—The Office of the Vice Provost for Research and Deerfield Management announce the inaugural request for proposals for Ancora Innovation, LLC, with a due date of June 4. An RFP information session is scheduled from 2 to 3:30 p.m. Friday, April 27, at Sarratt Student Center, Room 325.
Apr. 4, 2018—The Center for Technology Transfer and Commercialization's Alan Bentley will discuss emerging initiatives at Vanderbilt to engage industry more effectively, and a team from Deerfield Management will explain its collaborative approach to working with premier academic institutions to catalyze early stage therapeutic development.
Boehringer Ingelheim and Vanderbilt University expand partnership to develop novel treatment approaches for cancer
Mar. 14, 2018—New agreement will pursue therapies targeting MCL1 (myeloid cell leukemia 1), which is highly prevalent in many difficult-to-treat cancers.
Jan. 8, 2018—Under the terms of the licensing agreement, Lundbeck has exclusively licensed rights to compounds developed at Vanderbilt that act on a receptor in the brain that has been implicated in schizophrenia.
Sep. 28, 2017—The ranking is based on a number of indicators, including patent filings and research paper citations.